|| Checking for direct PDF access through Ovid
Maternal drug use in pregnancy may occur in different situations: chronic maternal disease prior to pregnancy, maternal disease not linked to pregnancy or complicating pregnancy and automedication. Studies in Europe and USA/Canada have shown high numbers of drugs used by pregnant women, up to 13 with prescrip-tion rates over 90% in France. This is a major healthcare issue for clinicians as more than 80% of the drugs used are used without knowledge of their safety/efficacy for the mother, have undetermined risks and possible adverse effects on the fetuses. In France, epidemiological data are insufficient to evaluate the drug use during pregnancy and the status of the drugs prescribed (licensed/off-label).MAG is a large multicenter and prospective study conducted using an electronic questionnaire. As a collaborative project, MAG Consor-tium includes clinical research units of APHP (CIC1426, CIC0901), the Gynaecology and Obstetrics-CIC network (GO-CIC), the «Risks and Pregnancy» University-Hospital de-partment and INSERM U953 unit.The objectives are to determine the extent of drug use during pregnancy, determine drug status, conditions of use (prescription/automedication), and to identify per-sonal, social and economic factors conditioning their use in a representative population of 1000 randomly selected pregnant women in France.Therefore, France was divided into 7 regions with 1 peri-natal network selected per region. Using childbirths ep-idemiological data from the French National Institute of Statistics and Economic Studies, a total of 35 maternity wards will participate: 5 units per region (1 level III, 2 level II, 2 level I) with 1 private unit to ensure the best repre-sentativeness of the results with recruitments established by region and by age groups. Seven mobile CRAs are in charge of the interviews using MAG electronic question-naire facilitating the capture and real-time monitoring of the inclusions with a list of 350 most used drugs (in preg-nant women) uploaded on the platform. MAG is conduct-ed over a period of 5 days in each centre.To date, the 35 maternity wards and the perina-tal networks have been identified within the 7 regions: Yvelines (MYPA), Pays de la Loire (Sécurité Naissance), Basse-Normandie, Bourgogne (Femme et Enfant), Rhône-Alpes (Aurore) and Provence Alpes Côte d’Azur (Méditer-ranée).From June 2016 to mid-March 2017, the MAG network allowed to recruit 860 patients in 16 centres with 13 com-pleted weeks and 10 days of study conduct, a mean of 58 women per centre (13 centres) or 12 women includ-ed per day. MAG interviews are less than 30 min per woman. A refusal rate of 15% was observed reflecting that MAG was very well received among pregnant wom-en. The MAG survey is still ongoing with inclusions sched-uled until June 2017. Inclusions will be extended up to 2000 patients.MAG study will deliver essential informa-tion of drug use in pregnant women identifying potential associated factors and determine drugs that would ne-cessitate complementary pharmacological studies. MAG will orientate information and communication strategies of health professionals and women to limit inappropriate drug exposures and provide the tools for future studies to be conducted through national surveillance networks.